Overview: JAK2 V617F Allelic Ratio TestIntroduction: The JAK2 V617F Allelic Ratio Test quantifies JAK2 V617F mutation to monitor myeloproliferative disorders, preventing relapse. Aligned with 2023 NCCN guidelines, it uses PCR for high sensitivity, supporting cancer screening. This test is critical for assessing disease burden, guiding treatment adjustments, and improving outcomes in molecular pathology for patients with myeloproliferative neoplasms.
Other Names: JAK2 V617F PCR Assay, Myeloproliferative MRD Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: JAK2 V617F testing emerged in 2005 with myeloproliferative disorder research. Quantitative PCR methods improved sensitivity for relapse monitoring.
Purpose: Quantifies JAK2 V617F mutation to monitor myeloproliferative disorders, guides therapy, and prevents relapse.
Test Parameters: 1. JAK2 V617F Allelic Ratio
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of myeloproliferative disorder treatment or symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document myeloproliferative disorder history, fatigue, or clotting. Include current medications, especially JAK inhibitors.
Consent: Written consent required, detailing the tests purpose, relapse monitoring, and risks of blood or bone marrow collection.
Procedural Considerations: Uses quantitative PCR to measure JAK2 V617F allelic ratio in whole blood, bone marrow, or saliva. Results are available in 3-5 days, supporting treatment decisions. Performed in laboratories, often for myeloproliferative disorder monitoring.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: High JAK2 V617F allelic ratio indicates persistent disease, guiding intensified therapy. Low or undetectable levels suggest remission, supporting continued monitoring.
Specialist Consultation: Consult a hematologist for result interpretation and treatment planning.
Additional Supporting Tests: JAK2 exon 12 PCR, CALR mutation testing, or bone marrow biopsy to monitor myeloproliferative disorders.
Test Limitations: Sensitivity depends on sample quality; clinical correlation is needed. Rare mutations may not be quantified.
References: NCCN Myeloproliferative Neoplasm Guidelines, 2023; Blood, Tefferi A, 2022.
